RELB and prostate cancer: Given that RelB and p52 have been shown to be activated in other tumour types such as B- and T-cell lymphomas as well as in breast carcinoma (Dejardin et al, 1998; Rayet and Gelinas, 1999; Cogswell et al, 2000), they may also play a role in prostate cancer development and progression.